Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000919574-25-001872
Filing Date
2025-03-07
Accepted
2025-03-07 20:22:34
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 12184
2 d11624278-ex99.htm EX-99 6740
  Complete submission text file 0000919574-25-001872.txt   20691
Mailing Address 1350 AVENUE OF THE AMERICAS SUITE 2600 NEW YORK NY 10019
Business Address 1350 AVENUE OF THE AMERICAS SUITE 2600 NEW YORK NY 10019 212.300.5575
Casdin Capital, LLC (Filed by) CIK: 0001534261 (see all company filings)

EIN.: 800752351 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Subject) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92757 | Film No.: 25721853
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)